Physician profile
Joseph Wilde
NPI 1972521581
$4,853.54
in general payments reported to CMS, 2019-2025
30 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $459 · 2021: $749 · 2022: $777 · 2023: $915 · 2024: $563 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168 · Education: $99.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.93 |
| Education | $99.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.77 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Genzyme Corporation | $578.22 | 2019-2025 | |
| Lilly USA, LLC | $538.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $395.05 | 2021-2025 | Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $347.48 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $281.31 | 2020-2024 | Dupixent |
| Janssen Biotech, INC. | $228.46 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $219.80 | 2019-2025 | Adbry |
| Pfizer INC. | $217.86 | 2019-2024 | |
| Amgen INC. | $183.32 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $157.24 | 2019-2025 | Klisyri |
| Galderma Laboratories, L.P. | $154.40 | 2019-2025 | Nemluvio |
| Ucb, INC. | $93.50 | 2021-2025 | Cimzia, Bimzelx |
| Dermira, INC. | $66.65 | 2019-2020 | |
| Biofrontera INC. | $64.45 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $53.56 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $51.88 | 2021-2023 | Poteligeo |
| Genentech USA, INC. | $51.36 | 2019-2020 | |
| Organogenesis INC. | $48.36 | 2022-2023 | Puraply |
| Organon LLC | $47.75 | 2024-2025 | |
| Incyte Corporation | $37.69 | 2024-2025 | Opzelura |
| Epi Health, LLC | $34.13 | 2021 | |
| Vyne Pharmaceuticals INC. | $31.13 | 2020-2021 | |
| Celgene Corporation | $23.88 | 2019 | |
| Journey Medical Corporation | $23.33 | 2022 | |
| Dusa Pharmaceuticals, INC. | $23.30 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.40 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.22 | 2024 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $19.36 | 2023 | Sotyktu |
| Aclaris Therapeutics, INC. | $16.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wilde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.